文章：

嵌合抗原受体T细胞疗法在急性髓系白血病中的应用：现状与最新进展

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances

原文发布日期：20 December 2023

DOI: 10.3390/cancers16010042

类型: Article

开放获取: 是

英文摘要：

Chimeric antigen receptors (CAR)-T-cell therapy represents the most important innovation in onco-hematology in recent years. The progress achieved in the management of complications and the latest generations of CAR-T-cells have made it possible to anticipate in second-line the indication of this type of treatment in large B-cell lymphoma. While some types of B-cell lymphomas and B-cell acute lymphoid leukemia have shown extremely promising results, the same cannot be said for myeloid leukemias—in particular, acute myeloid leukemia (AML), which would require innovative therapies more than any other blood disease. The heterogeneities of AML cells and the immunological complexity of the interactions between the bone marrow microenvironment and leukemia cells have been found to be major obstacles to the clinical development of CAR-T in AML. In this review, we report on the main results obtained in AML clinical trials, the preclinical studies testing potential CAR-T constructs, and future perspectives.

摘要翻译： 

嵌合抗原受体（CAR）-T细胞疗法代表了近年来血液肿瘤学领域最重要的创新。在并发症管理方面取得的进展以及最新一代CAR-T细胞的出现，使得在二线治疗中考虑将此类疗法应用于大B细胞淋巴瘤成为可能。尽管某些类型的B细胞淋巴瘤和B细胞急性淋巴细胞白血病已显示出极具前景的疗效，但髓系白血病——尤其是急性髓系白血病（AML）的情况却并非如此，而AML恰恰比其他血液疾病更需要创新疗法。研究发现，AML细胞的异质性以及骨髓微环境与白血病细胞之间相互作用的免疫复杂性，是CAR-T疗法在AML临床发展中面临的主要障碍。本综述将系统阐述AML临床试验取得的主要成果、测试潜在CAR-T结构的临床前研究以及未来展望。

原文链接：

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances